 |
|
|
| |
Evaluation of T-cell immunosenescence markers in virologically suppressed people living with HIV aged over 60 years on BIC/FTC/TAF or DTG/3TC: the Collateral study
|
| |
| |
Results
From August 2023 to June 2024, we analyzed 49 PLWH, 23 on BIC/FTC/TAF and 26 taking DTG/3TC (mean age 69.5, years since HIV diagnosis 28.8, years on ART 23.6, CD4 at inclusion 583 cc/mm3, 49% with nadir CD4 < 200 cc/mm3). Five healthy
individuals, matched for age, were included as controls.
PWH had higher immunosenescence markers than healthy subjects. Among PWH, no significant differences were found between those taking BIC/FTC/TAF compared to DTG/3TC (data not shown).
In case of nadir CD4 < 200 cells/mm3, those with triple ART had significantly lower levels of senescent and TEMRA CD4+ and CD8+ cells compared with those taking dual therapy, despite similar age, years since HIV diagnosis, time on ART, CD4 at
inclusion and number of comorbid conditions. Moreover, a trend was found for lower CD4/CD8 ratio among those on dual ART and low CD4 nadir (Table 1).
|
| |
|
|
|
|
|
